我們已在上線！進一步了解

Tonix Pharmaceuticals

TNXP

市值 US$1.04億

6.04 USD

-0.38

5.92%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

6.06

+0.02

0.33%

1天

-5.92%

5天

-16.57%

1個月

-48.64%

3個月

-49.03%

6個月

-57.25%

今年迄今

-63.5%

1年

-67.89%

5年

-100%

10年

-100%

關於： Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

員工： 142

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 25%

中性 75%

負面 0%

Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026

BERKELEY HEIGHTS, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced an oral presentation on TNX-801, a live, attenuated, minimally replicative investigational vaccine platform based on horsepox virus to protect against mpox and other infectious diseases, and a working group session led by Tonix, “Vectored Vaccine Platforms: From Design to Improving Efficacy,” at the World Vaccine Congress Europe held in Amsterdam, Netherlands on October 19-21, 2026.

Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026

Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®

New agreement, effective immediately, adds approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.) Commercial and government payer coverage for TONMYA now reaches approximately 166 million covered lives (53% of total U.S. lives) BERKELEY HEIGHTS, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced a second major managed Medicare agreement for TONMYA® (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults that is effective immediately, adding approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.).

Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®

Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears

Tonix Pharmaceuticals NASDAQ: TNXP CEO Seth Lederman told attendees at the Cantor Healthcare Conference that the company's near-term focus is the commercial launch of TONMYA, its FDA-approved treatment for fibromyalgia in adults, while it advances development programs in Lyme disease prevention and transplant rejection.

Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

BERKELEY HEIGHTS, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced the promotion of Thomas Englese to Chief Commercial Officer, effective immediately.

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference

BERKELEY HEIGHTS, N.J., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced that the management team will participate in a fireside chat and 1x1s at Cantor's 2026 Global Healthcare Conference, being held September 9-11, 2026, in New York.

Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference

Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline

Tonix Pharmaceuticals NASDAQ: TNXP is focusing its near-term strategy on the commercial launch of TONMYA for fibromyalgia while advancing development programs in Lyme disease prevention and major depressive disorder, Chief Executive Officer Seth Lederman said during a Canaccord Genuity conference presentation.

Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline

Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript

Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript

Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript

Tonix Pharmaceuticals Q2 Earnings Call Highlights

Tonix Pharmaceuticals NASDAQ: TNXP reported second-quarter 2026 net product revenue of approximately $13.5 million, led by $11 million in sales of fibromyalgia treatment Tonmya. The company said Tonmya sales rose 197% from the first quarter, its second full quarter of commercial sales following the product's November launch.

Tonix Pharmaceuticals Q2 Earnings Call Highlights

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered lives (43% of total U.S. lives) First patient enrolled in Phase 2 HORIZON study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of major depressive disorder (MDD) Phase 2 adaptive field study of TNX-4800 for the prevention of Lyme disease in the U.S. on track to start in the first quarter of 2027 pending final FDA review and agreement on study protocol Approximately $176.2 million in cash and cash equivalents as of June 30, 2026 Conference call today at 8:30 a.m. ET BERKELEY HEIGHTS, N.J.

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

BERKELEY HEIGHTS, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biotechnology company, today announced that the management team will participate in two upcoming investor conferences in August and September 2026.

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

查看新聞排名

價格圖表採用Lightweight Charts™實作